Prophylaxis Against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin

American Journal of Transplantation

Volumn 10, Issue 8, 2010, Pages 1861-1869

  Jiang, L ^a,b   Yan, L ^a   Li, B ^a   Wen, T ^a   Zhao, J ^a   Cheng, N ^b   Wei, Y ^a   Yang, J ^a   Xu, M ^a   Wang, W ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Hepatitis B immunoglobulin; lamivudine; liver transplantation; prevention; viral infection

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE; PREDNISONE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE; VIRUS LOAD;

ADULT; AGED; COSTS AND COST ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; INJECTIONS, INTRAMUSCULAR; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 77954897950     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03208.x     Document Type: Article

References (33)

1. Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003 75 (3 Suppl S41 S44.
2. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004 10 (10 Suppl 2 S74 S85.
3. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991 13 : 619 626.
4. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 329 : 1842 1847.
5. Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 2005 39 : 58 63.
6. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998 27 : 213 222.
7. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998 27 : 254 263.
8. Lee KW, Lee DS, Lee HH et al. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 2004 36 : 2311 2312.
9. Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: Review and university of Tokyo experience. Dig Dis Sci 2007 52 : 2472 2477.
10. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996 348 : 1212 1215.
11. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 33 : 424 432.
12. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998 28 : 585 589.
13. Steinmuller T, Seehofer D, Rayes N et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002 35 : 1528 1535.
14. Dan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis. Liver Transpl 2006 12 : 736 746.
15. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 132 : 931 937.
16. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000 6 : 429 433.
17. Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006 12 : 253 258.
18. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005 11 : 402 409.
19. Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000 31 : 207 210.
20. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001 34 : 411 416.
21. Seehofer D, Rayes N, Naumann U et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001 72 : 1381 1385.
22. Woo HY, Choi JY, Jang JW et al. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 2008 80 : 1891 1899.
23. Rosenau J, Bahr MJ, Tillmann HL et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001 34 : 895 902.
24. Marzano A, Lampertico P, Mazzaferro V et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005 11 : 532 538.
25. Tur-Kaspa R, Shaul Y, Moore DD et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988 167 : 630 633.
26. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995 22 : 36 43.
27. Chui AK, Chan CJ, Rao AR et al. Immunosuppression with rapid steriod reduction among predominantly HBV liver transplantation recipients: Initial experience. Transplant Proc 2003 35 : 419 420.
28. Roche B, Feray C, Gigou M et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003 38 : 86 95.
29. Karademir S, Astarcioglu H, Akarsu M et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006 38 : 579 583.
30. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: Comparison with other HBIG regimens. Clin Transplant 2007 21 : 510 517.
31. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001 120 : 1828 1853.
32. Seehofer D, Rayes N, Berg T et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int 2000 13 : 290 296.
33. Marzano A, Salizzoni M, Debernardi-Venon W et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001 34 : 903 910.